Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors.

The PI3K/AKT/mTOR and PIM kinase pathways contribute to the development of several hallmarks of cancer. Cotargeting of these pathways has exhibited promising synergistic therapeutic effects in liquid and solid tumor types. To identify molecules with combined activities, we cross-screened our collection of PI3K/(±mTOR) macrocycles (MCXs) and identified the MCX thieno[3,2-]pyrimidine derivative as a moderate dual PI3K/PIM-1 inhibitor.

Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors.

Activation of the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway occurs frequently in a wide range of human cancers and is a main driver of cell growth, proliferation, survival, and chemoresistance of cancer cells. Compounds targeting this pathway are under active development as anticancer therapeutics and some of them have reached advanced clinical trials or been approved by the FDA. Dual PI3K/mTOR inhibitors combine multiple therapeutic efficacies in a single molecule by inhibiting the pathway both upstream and downstream of AKT.

Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.

PIM kinase family (PIM-1, PIM-2 and PIM-3) is an appealing target for the discovery and development of selective inhibitors, useful in various disease conditions in which these proteins are highly expressed, such as cancer. The significant effort put, in the recent years, towards the development of small molecules exhibiting inhibitory activity against this protein family has ended up with several molecules entering clinical trials. As part of our ongoing exploration for potential drug candidates that exhibit affinity towards this protein family, we have generated a novel chemical series of triazolo[4,3-b]pyridazine based tricycles by applying a scaffold hopping strategy over our previously reported potent pan-PIM inhibitor ETP-47453 (compound 2).

Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.

The involvement of the phosphoinositide 3-kinases (PI3Ks) in several diseases, especially in the oncology area, has singled it as one of the most explored therapeutic targets in the last two decades. Many different inhibitor classes have been developed by the industry and academia with a diverse selectivity profile within the PI3K family. In the present manuscript we report a further exploration of our lead PI3K inhibitor ETP-46321 (Martínez González et al.

Synthesis of a Crushed Fullerene C60H24 through Sixfold Palladium-Catalyzed Arylation.

The synthesis of a new -symmetric crushed fullerene CH () has been accomplished in three steps from truxene through sixfold palladium-catalyzed intramolecular arylation of a -trialkylated truxene precursor. Laser irradiation of induces cyclodehydrogenation processes that result in the formation of C, as detected by LDI-MS.

PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.

Currently, there is no efficient therapy for patients with peripheral T cell lymphoma (PTCL). The Proviral Integration site of Moloney murine leukemia virus (PIM) kinases are important mediators of cell survival. We aimed to determine the therapeutic value of PIM kinases because they are overexpressed in PTCL patients, T cell lines and primary tumoral T cells.

Molecular panels for energy transduction in C60-based conjugates.

Light-harvesting C(60)-based dyads endowed with a truxene fluorophore unit have been synthesized. Their photophysical studies in solution reveal a singlet-singlet energy transfer deactivation mechanism that confirms the actuation of the latter as an efficient molecular panel for light absorption and energy transduction. Those processes strongly depend on the nature of the linker connecting both chromophores, such as C(60) and truxene, owing to the overlapping degree between their respective orbitals.

Synthesis of C3 benzo[1,2-e:3,4-e':5,6-e"]tribenzo[l]acephenanthrylenes ("crushed fullerene" derivatives) by intramolecular palladium-catalyzed arylation.

The C60 polyarenes 4, 5, 18 a, and 18 b have been synthesized from truxene by triple alkylation at C5, C10, and C15 followed by a palladium-catalyzed intramolecular arylation. The synthesis of "crushed fullerene" C60H30 (2) is the most efficient reported to date and proceeds in 33% overall yield.